A tale of two Covids for smaller device makers
The pandemic provided the best and worst of times for smid-cap medtechs.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
The extremes converge in big medtech’s hiring practices
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
MD Start bucks the trend for later-stage medtech investing
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
Deals galore for a new generation of transcatheter mitral valves
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.